The group reported a sales increase of 14% to $21.4bn and a similar rise in operating profit at $4.8bn. A strong performance from its more established products helped soothe regulatory problems with its Exanta and Iressa drug lines.
However under IFRS operating profit would have fallen to $4.5bn and earnings per share would drop $0.10 to $2.18. It also advised that EPS guidance for 2005 would be around $0.05 lower than under UK GAAP.
AstraZeneca will produce it first results under IFRS when it releases figures for the first quarter of the year.
Does Darwin's theory apply to taxation? Colin ponders...
The EC has been instructed to draft a European Union (EU) directive authorising an EU financial transaction tax, which would apply to ten of the EU’s 28 member states
Accountancy watchdog the FRC has dropped its investigation into the former chief financial officer of Tesco, nearly two years after the supermarket was engulfed in an accounting scandal
Colin imagines how Apple's logo might change in the wake of the EC's ruling over its Irish tax arrangements